Recent Developments in Anti-Cancer Agents Targeting PI3K, Akt and mTORC1/2

Publisher： Bentham Science Publishers

E-ISSN： 2212-3970|6|2|210-236

ISSN： 1574-8928

Source： Recent Patents on Anti-Cancer Drug Discovery, Vol.6, Iss.2, 2011-05, pp. : 210-236

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 13, Iss. 7, 2013-09 ,pp. : 1048-1056

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 13, Iss. 10, 2013-12 ,pp. : 1552-1564

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Developments in Patent Anti-Cancer Agents Targeting the Matrix Metalloproteinases (MMPs)

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 5, Iss. 2, 2010-06 ,pp. : 109-141

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the PI3K/Akt/mTOR Axis by Apigenin for Cancer Prevention

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 13, Iss. 7, 2013-09 ,pp. : 971-978

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Developments in Anti-Cancer Agents Targeting the Ras/Raf/ MEK/ERK Pathway

By  

Recent Patents on Anti-Cancer Drug Discovery, Vol. 4, Iss. 1, 2009-01 ,pp. : 28-35

Bentham Science Publishers

Access to resources Recommend Favorite